Background and Aims: Cardiovascular disease is the leading cause of death among end-stage renal disease (ESRD) patients with hypercholesterolemia as a major cause. A few studies have demonstrated counter-intuitive findings known as reverse epidemiology where normal levels of cholesterol are associated with higher levels of mortality. The purpose of this study was to determine if there are reverse epidemiological associations between lipid risk factors and mortality in ESRD patients. Methods: ESRD (n = 438) patients were recruited from 4 outpatient dialysis units. Patients were tracked for 36 months until study completion or death with mortality status as the outcome measure. Results: Analysis of covariance revealed significant differences at posttest and reverse epidemiological effects for total cholesterol (p = 0.0001), low-density lipoprotein cholesterol (LDL) (p = 0.023), LDL particle number (p = 0.0001), LDL size (p = 0.009), triglycerides (p = 0.0001), and very low-density lipoprotein cholesterol (p = 0.036). A step-wise linear regression revealed weak, but significant predictors of mortality with total cholesterol (β = 0.263, p = 0.017) and LDL (β = –0.177, p = 0.045). A Cox death hazard ratio revealed LDL size as a significant predictor of mortality in this study. Conclusions: Our study discovered reverse epidemiology in a number of lipid variables. Additionally regression revealed that LDL and total cholesterol were predictors of mortality with lower levels being more predictive of death.

Keywords:
Cardiovascular disease, Dyslipidemia, End-stage renal disease, Hypercholesterolemia, LDL cholesterol, Lipids
1.
Junyent M, Martínez M, Borràs M, et al: Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol 2010;11:14.
2.
Tsirpanlis G, Boufidou F, Zoga M: Low cholesterol along with inflammation predicts morbidity and mortality in hemodialysis patients. Hemodial Int 2009;13:197–204.
3.
Chavalitdhamrong D, Danovitch GM, Bunnapradist S: Is there a reversal of reverse epidemiology in renal transplant recipients? Semin Dial 2007;20:544–548.
4.
Nanayakkara PWB, Gaillard CAJM: Vascular disease and chronic renal failure: new insights. Neth J Med 2010;68:5–14.
5.
Sagheb MM, Ostoven MA, Sohrabi Z, et al: Hyperhomocysteinemia and cardiovascular risk in hemodialysis patients. Saudi J Kidney Dis Transpl 2010;21:863–866.
6.
US Renal Data System: Excerpts from the USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2006;47(suppl 1):1–286.
7.
Kilpatrick RD, McAllister CJ, Kovesdy CP, et al: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293–303.
8.
Chmielewski M, Carrero JJ, Nordfors L, et al: Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008;21:635–644.
9.
Dungan KM, Guster T, DeWalt D, Buse JB: A comparison of lipid and lipoprotein measurement in the fasting and nonfasting states in patients with type 2 diabetes. Curr Med Res Opin 2007;23:2689–2695.
10.
Bowden RG, Griggs J, Wilson RL, Gentile M: Cholesterol values are poor markers of disease risk in a chronic disease population. Clin Lipidol 2009;4:545–551.
11.
Kovesdy CP, Anderson JE: Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial 2007;20:566–569.
12.
Liu Y, Coresh J, Eustace JA, et al: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451–459.
13.
Bowden RG, Wilson RL: Malnutrition, inflammation and lipids in a cohort of dialysis patients. Postgrad Med 2010;122:196–202.
14.
Bowden RG, Hebert S, Wilson R, et al: Comparison of lipid measures and risk stratification among end-stage renal disease patients. J Nephrol 2007;21:212–218.
15.
Diepeveen SHA, Wetzels JFM, Bilo HJG, van Tits LGH, Stalenhoef AFH: Cholesterol in end-stage renal disease: the good, the bad or the ugly? Neth J Med 2008;66:51–63.
16.
Balakrishnan VS, Rao M: Genetics and reverse epidemiology among patients on chronic hemodialysis. Semin Dial 2007;20:570–576.
17.
Nurmohamed SA, Nubé MJ: Reverse epidemiology: paradoxical observations in haemodialysis patients. Neth J Med 2005;63:376–381.
18.
Kalantar-Zadeh K: Recent advances in understanding the malnutrition-inflammation cachexia syndrome in chronic kidney disease patients: what is next? Semin Dial 2005;18:365–369.
19.
Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004;15:442–453.
20.
Curtis JP, Selter JG, Wang Y, et al: The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55–61.
21.
Cano NJ, Pichard C, Roth H, et al: C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004;126:540–546.
22.
Horwich TB, Fonarow GC: Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 2007;20:549–553.
23.
Escalante A, Haas RW, del Rincon I: Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005;165:1624–1629.
24.
Bowden RG, Hebert S, Wilson, et al: A cholesterol primer for health professionals. Calif J Health Promotion 2006;4:12–21.
25.
Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ: Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2003;46:674–682.
26.
Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002;61:2240–2249.
27.
Guarnieri GF, Moracchiello M, Campanacci L, et al: Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 1978;8:S26–S30.
28.
McLeod R, Reeve CE, Frohlich J: Plasma lipoproteins and lecithin: cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 1984;25:683–688.
29.
Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262–F272.
30.
Dantoine TF, Debord J, Charmes JP, et al: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1988;9:2082–2088.
31.
Trivedi H, Xiang Q, Klein JP: Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrol Dial Transplant 2009;24:258–266.
32.
Marcovecchio ML, Dalton RN, Prevost AT, et al: Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type I diabetes. Diabetes Care 2009;32:658–666.
33.
Balakrishnan VS, Rao M: Genetics and reverse epidemiology among patients on chronic hemodialysis. Semin Dial 2007;20:570–576.
34.
Porazko T, Kuzniar J, Kusztal M, et al: IL-18 is involved in vascular injury in end-stage renal disease patients. Nephrol Dial Transplant 2009;24:589–596.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.